Cubist Gets Option To Acquire Illumigen; Funds HCV Drug Oct. 18, 2007 By Trista Morrison Cubist Pharmaceuticals Inc. moved to expand its pipeline beyond Cubicin (daptomycin for injection) by picking up an exclusive option to acquire Illumigen Biosciences Inc. (BioWorld Today)Read More